Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR-T2 in R/R CD19+ Acute Leukemia
NCT02822326Phase 1Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2016
- Primary completion
- Sep 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19-CAR-T2 Cells in B-cell acute lymphoblastic leukemia (B-ALL), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Maximum Tolerated Dose at 24 weeks. Status: unknown.
02
Drugs
CD19-CAR-T2 Cells
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02822326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02822326.